Clinical context A 29-year-old with recurrent vulvovaginal candidiasis is scheduled for another ibrexafungerp course; the nurse reviews pregnancy status, newly added medicines, interaction management, and administration plans. Highlight the medication-reconciliation findings that require clarification before the next ibrexafungerp dose.
Highlight in Table
Choose your responses, then check the answer.
Explanation
Pregnancy is a contraindication. A strong CYP3A inhibitor requires a labeled dose modification, while a strong or moderate CYP3A inducer should be avoided because it can reduce ibrexafungerp exposure.
Quick answer Highlight pregnancy and clinically important CYP3A conflicts.
Why this is correct Safe administration includes pregnancy-status verification for reproductive-potential clients and a complete interaction review. Benign administration details do not resolve a contraindication or major exposure change.
Easy analogy or mental picture Build a medication-safety chain: identify the changing cue, connect it to the labeled toxicity or interaction, interrupt preventable exposure, stabilize the client, and verify a measurable response.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, or delay escalation leave the client at risk.
Clinical contextA 29-year-old with recurrent vulvovaginal candidiasis is scheduled for another ibrexafungerp course; the nurse reviews pregnancy status, newly added medicines, interaction management, and administration plans.